Methyclothiazide


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Oedema 2.5-5 mg once daily, in the morning. Max: 10 mg/day. HTN 2.5-5 mg once daily, either alone or w/ other antihypertensives.
Contraindications
Hypersensitivity to sulfonamide-derived drugs, anuria.
Special Precautions
Patient w/ fluid and electrolyte disturbances, gout, DM, hypercholesterolaemia, parathyroid disease, history of allergy and bronchial asthma. May exacerbate SLE. Hepatic and renal impairment. Pregnancy and lactation. Monitoring Parameters Assess wt, input and output reports daily to determine fluid loss, BP, serum electrolytes, BUN, creatinine.
Adverse Reactions
Headache, cramping, weakness, orthostatic hypotension, pancreatitis, jaundice, sialadenitis, vomiting, diarrhoea, nausea, gastric irritation, constipation, anorexia, aplastic anaemia, haemolytic anaemia, agranulocytosis, leukopenia, thrombocytopenia, anaphylactic reactions, necrotising angiitis, Stevens-Johnson syndrome, resp distress, fever, purpura, urticaria, rash, photosensitivity, hyperglycemia, hyperuricemia, electrolyte imbalance, vertigo, dizziness, paraesthesia, muscle spasm, restlessness, transient blurred vision, xanthopsia, glycosuria.
B D if used in gestational HTN.
Drug Interactions
Increased risk of lithium toxicity. Hypokalaemia may develop during concomitant use of steroids or ACTH. Insulin requirement in DM patients may be altered. Decreased arterial responsiveness to norepinephrine. Increased responsiveness to tubocurarine. Potentiation of orthostatic hypotension by barbiturates or narcotics.
CIMS Class
ATC Classification
C03AA08 - methyclothiazide ; Belongs to the class of low-ceiling thiazide diuretics.
Disclaimer: This information is independently developed by CIMS based on methyclothiazide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in